The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics

Journal of Clinical Psychiatry

Volumn 59, Issue 2, 1998, Pages 69-75

  Miller, Carl H ^c   Mohr, Fritz ^a   Umbricht, Daniel ^a   Woerner, Margaret ^a   Fleischhacker, W Wolfgang ^d   Lieberman, Jeffrey A ^b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATENOLOL; BENZATROPINE MESILATE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DESIPRAMINE; DIAZEPAM; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; LOXAPINE SUCCINATE; MOLINDONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OXAZEPAM; PERPHENAZINE; PROCYCLIDINE; PROPRANOLOL; RISPERIDONE; SERTRALINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; VENLAFAXINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GAIT DISORDER; HUMAN; HYPERSALIVATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; PERSONALITY DISORDER; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOIDISM; SCHIZOPHRENIA; TREMOR;

EID: 0031936086     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n0205     Document Type: Article

References (34)

1. Casey DE. Extrapyramidal syndromes: epidemiology, pathophysiology and the diagnostic dilemma. CNS Drugs 1996;5:1-12
2. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
3. Fitton A, Hell R. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drug Evaluation 1990;40:722-797
4. Kurz M, Hummer M, Oberbauer H, et al. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacol 1995;118:52-56
5. Chouinard G, Jones B, Remington GJ, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
6. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double blind, parallel group study versus haloperidol. Br J Psychiatry 1995;166:712-726
7. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
8. Meltzer HY. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation in Progress. New York, NY: Raven Press; 1996:1277-1286
9. Claus A, Bollen J, DeCuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double blind comparative study. Acta Neurol Scand 1992;83:295-305
10. Min S, Rhee C, Kim C, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double blind comparative trial. Yonsei Med J 1993;34:179-196
11. Barnes TRE. A rating scale for drug induced akathisia. Br J Psychiatry 1989;154:672-676
12. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;213:11-19
13. van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72
14. Kane JM. Schizophrenia [Drug Therapy]. N Engl J Med 1996;334:34-41
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:1-357
16. Claghorn J, Honigfeld G, Abuzzahab FS, et al. The risk and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7: 377-384
17. Chengappa KNR, Shelton MD, Baker RW, et al. The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 1994; 55:142-145
18. Lieberman JA, Kane JM, John CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50:329-338
19. Klieser E, Lehmann E, Kinzler E, et al. Randomized, double blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1994;15:45-51
20. Fritze J, Elliger T. Pirenzepine for clozapine-induced hypersalivation [letter]. Lancet 1995;346:1034
21. Grabowski J. Clonidine treatment of clozapine induced hypersalivation. J Clin Psychopharmacol 1992;12:69-70
22. Huttunen M. The evolution of the serotonin dopamine concept. J Clin Psychopharmacol 1995;15:4S-10S
23. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis in schizophrenia. Psychopharmacology (Berl) 1989;99:18-27
24. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-287
25. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1,D2 and serotonin pKi values. J Pharmacol Exp Ther 1989;251:238-246
26. Casey DE. Serotonergic and dopaminergic aspects of neuroleptic induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology (Berl) 1994;112(suppl 1):S55-S59
27. Farde L, Nordström AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544
28. Kapur S, Remington GJ, Zipursky RB, et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57:103-107
29. Nyberg S, Farde L, Eriksson L, et al. 5HT2 and D2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology (Berl) 1993;110:265-272
30. Farde L, Nyberg S, Oxenstierna G, et al. Positron emission tomography studies on D2 and 5HT2 receptor binding in risperidone treated schizophrenic patients. J Clin Psychopharmacol 1995;15:19S-23S
31. Miller CH, Fleischhacker WW, Ehrmann H, et al. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 1990;26:373-376
32. Bersani G, Grispini A, Marini S, et al. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990;13:500-506
33. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychol Med 1980;10:55-72
34. Owens DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55(5, suppl):29-35